AbbVie announced the launch of Creon (pancrelipase) 36,000 lipase-unit delayed-release capsules for the treatment of patients with exocrine pancreatic insufficiency (EPI) due to cystic fibrosis, ...

CREON (Lipase, amylase, protease) e-c minimicrospheres in capsules by AbbVie Creon (pancrelipase, from Solvay Pharmaceuticals) delayed-release capsules, a pancreatic enzyme product (PEP), has received ...

ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON® (pancrelipase) ...

International Journal of Pharmceutics: In Vitro: The dissolution characteristics of five capsules (Next Generation Enteric [NGE], Vcaps® Enteric [VCE], VCE DUOCAP® [VCE/VCE] system, Hard Gelatin ...

May 7, 2009 — Pancrelipase (Creon, Solvay Pharmaceuticals, Inc) delayed-release capsules were approved by the US Food and Drug Administration (FDA) for treatment of exocrine pancreatic insufficiency ...

Uses CREON (pancrelipase) Delayed-Release Capsules is a prescription pancreatic enzyme medicine used to improve food digestion in people who cannot digest food properly because they have exocrine ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. CREON contains the active ingredient Pancreatic extract. CREON is used ...

Abbott announced that the US Food and Drug Administration (FDA) has approved an infant-specific dose of CREON (pancrelipase) delayed-release capsules to treat Exocrine Pancreatic Insufficiency (EPI) ...

NORTH CHICAGO, Ill., May 30, 2013 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that a new, higher-dose capsule of CREON ® (pancrelipase) Delayed-Release Capsules is commercially available in ...

Pancreatic cancer patients are forced to call pharmacies across the UK to track down the life-saving medication that they rely on to eat and digest meals due to a severe drug shortage. Pancreatic ...